HeartBeam, Inc.

HeartBeam, Inc.(BEAT)の株式分析

$0.470

+0.003 (+0.66%)終値時点

Loading chart…
High
0.478
Open
0.470
VWAP
0.47
Vol
181.75K
Mkt Cap
66.09M
Low
0.463
Amount
85.45K
EV/EBITDA, TTM
0.00

HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.

AI analysis of HeartBeam, Inc. (BEAT)

sell

Heartbeam Inc is not a good buy right now due to its current price of $0.47, which is significantly below the analyst price targets of $2 and $5. The stock has a low RSI of 33.905, indicating it is oversold, but the ongoing losses, with a net income of -$4.7 million in Q1 2026 and a year-to-date change of -80.79%, raise concerns about its financial health. The main risk is the company's high negative cash flow, with a cash and cash equivalents total of only $2 million, down from $4.4 million, indicating liquidity issues.

Analyst Ratings (7)

+1140.43% upside
Buy
7 Buy
0 Hold
0 Sell
Current: 0.47
安値
4.00
平均
5.83
高値
8.00

Maxim

2026-07-14

目標株価

$2

Buy

Benchmark

2026-05-15

目標株価

$5

Speculative Buy

D. Boral Capital

2026-04-20

目標株価

Hold

Roth Capital

2025-10-31

目標株価

$4

Buy

Benchmark

2024-11-15

目標株価

$8

Buy

バリュエーション指標

The current forward P/E ratio for HeartBeam, Inc. (BEAT) is 0.00, compared to its 5-year average forward P/E of -2.80.

Forward P/E

Strongly Overvalued
5Y Average P/E
-2.80
Current P/E
0.00
割高
-1.46
割安
-4.15

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.14
Current EV/EBITDA
0.00
割高
0.44
割安
-0.72

Forward P/S

Fair
5Y Average P/S
75.69
Current P/S
5.44
割高
341.05
割安
-189.67

Alphio AI Price Scenarios for BEAT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BEAT

$1.70

シナリオ価格

B

Base

Base · 50%BEAT

$1.50

シナリオ価格

B

Bear

Bear · 25%BEAT

$1.28

シナリオ価格

イベントタイムライン

2026-08-13 (ET)

16:30:00

Company Expects Q4 2026 Cash Outflow Below $2.5 Million

16:30:00

HeartBeam Accelerates Heart Attack Detection Program

2026-07-14 (ET)

08:02:00

HeartBeam Secures New Patent Expanding ECG Device Capabilities

2026-06-30 (ET)

07:30:00

HeartBeam Completes Patient Enrollment in ALIGN-ACS Study

2026-06-24 (ET)

16:30:00

HeartBeam Announces Reorganization to Enhance Market Reach and Capital Efficiency

ニュース

BEAT FAQ — answered by Alphio AI

HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Heartbeam Inc is not a good buy right now due to its current price of $0.47, which is significantly below the analyst price targets of $2 and $5. The stock has a low RSI of 33.905, indicating it is oversold, but the ongoing losses, with a net income of -$4.7 million in Q1 2026 and a year-to-date change of -80.79%, raise concerns about its financial health. The main risk is the company's high negative cash flow, with a cash and cash equivalents total of only $2 million, down from $4.4 million, indicating liquidity issues.

7 analysts cover BEAT: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.83.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める